Total Payments
$280,772
2024 Payments
$43,960
Companies
65
Transactions
684
Medicare Patients
1,795
Medicare Billing
$336,839
Payment Breakdown by Category
Other$210,019 (74.8%)
Consulting$48,006 (17.1%)
Food & Beverage$15,205 (5.4%)
Travel$6,221 (2.2%)
Education$1,321 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $185,082 | 69 | 65.9% |
| Consulting Fee | $48,006 | 51 | 17.1% |
| Honoraria | $24,937 | 6 | 8.9% |
| Food and Beverage | $15,205 | 516 | 5.4% |
| Travel and Lodging | $6,221 | 23 | 2.2% |
| Education | $1,321 | 19 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $101,502 | 117 | $0 (2024) |
| Amgen Inc. | $51,173 | 78 | $0 (2023) |
| Rigel Pharmaceuticals, Inc. | $51,002 | 47 | $0 (2024) |
| ADC Therapeutics America, Inc. | $16,865 | 18 | $0 (2024) |
| Janssen Biotech, Inc. | $12,770 | 56 | $0 (2024) |
| Genentech USA, Inc. | $8,227 | 5 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $6,456 | 5 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $5,244 | 4 | $0 (2024) |
| Celgene Corporation | $5,154 | 20 | $0 (2023) |
| Janssen Pharmaceuticals, Inc | $3,755 | 16 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $43,960 | 132 | E.R. Squibb & Sons, L.L.C. ($16,380) |
| 2023 | $41,581 | 118 | Rigel Pharmaceuticals, Inc. ($15,366) |
| 2022 | $56,491 | 169 | Rigel Pharmaceuticals, Inc. ($24,722) |
| 2021 | $26,558 | 115 | Amgen Inc. ($10,076) |
| 2020 | $13,851 | 26 | Amgen Inc. ($6,834) |
| 2019 | $42,053 | 39 | E.R. Squibb & Sons, L.L.C. ($29,401) |
| 2018 | $24,268 | 42 | Amgen Inc. ($12,197) |
| 2017 | $32,009 | 43 | E.R. Squibb & Sons, L.L.C. ($11,155) |
All Payment Transactions
684 individual payment records from CMS Open Payments — Page 1 of 28
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Food and Beverage | In-kind items and services | $25.29 | General |
| Category: Oncology | ||||||
| 12/18/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $4.27 | General |
| Category: ONCOLOGY | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $15.03 | General |
| Category: Cardiovascular | ||||||
| 12/14/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $13.05 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $27.66 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,566.00 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Nubeqa, Vitrakvi | Food and Beverage | In-kind items and services | $34.99 | General |
| Category: Oncology | ||||||
| 12/04/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $16.52 | General |
| 12/02/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $25.22 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/27/2024 | Adaptive Biotechnologies Corporation | clonoSEQ (Device) | Food and Beverage | Cash or cash equivalent | $18.82 | General |
| Category: ONCOLOGY | ||||||
| 11/27/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $8.98 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 11/26/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $17.85 | General |
| Category: HORMONE THERAPY | ||||||
| 11/25/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $20.86 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/22/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Janssen Biotech, Inc. | TALVEY (Biological), TECVAYLI, DARZALEX | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: Oncology | ||||||
| 11/08/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $26.81 | General |
| Category: Oncology | ||||||
| 11/07/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,384.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/07/2024 | ADC Therapeutics America, Inc. | — | Food and Beverage | In-kind items and services | $29.96 | General |
| 11/06/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $83.20 | General |
| Category: Oncology | ||||||
| 11/05/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $29.96 | General |
| Category: ONCOLOGY | ||||||
| 11/04/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: ONCOLOGY | ||||||
| 10/30/2024 | SpringWorks Therapeutics, Inc. | OGSIVEO (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DESMOID TUMORS | ||||||
| 10/29/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $21.60 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/29/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/25/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,137.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 590 | 1,367 | $289,202 | $114,763 |
| 2022 | 7 | 622 | 1,220 | $251,554 | $107,856 |
| 2021 | 6 | 337 | 860 | $184,343 | $80,677 |
| 2020 | 6 | 246 | 394 | $93,351 | $33,543 |
Total Patients
1,795
Total Services
3,841
Medicare Billing
$336,839
Procedure Codes
32
All Medicare Procedures & Services
32 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 397 | 1,001 | $224,224 | $92,142 | 41.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 18 | 66 | $21,576 | $6,357 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 71 | $10,721 | $4,845 | 45.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 24 | 24 | $9,559 | $3,363 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 20 | 20 | $6,820 | $2,426 | 35.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 14 | $4,214 | $2,030 | 48.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $4,708 | $1,653 | 35.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 20 | 88 | $4,664 | $1,013 | 21.7% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 15 | 15 | $795.00 | $470.55 | 59.2% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 13 | 13 | $689.00 | $407.81 | 59.2% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 13 | 44 | $1,232 | $55.91 | 4.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 393 | 884 | $198,016 | $86,012 | 43.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 129 | 196 | $29,596 | $13,056 | 44.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 37 | 37 | $12,617 | $4,468 | 35.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 14 | 14 | $4,214 | $2,117 | 50.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $3,136 | $1,117 | 35.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 24 | 63 | $3,339 | $717.88 | 21.5% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 11 | 12 | $636.00 | $368.25 | 57.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 161 | 598 | $133,952 | $60,329 | 45.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 61 | 61 | $20,801 | $7,852 | 37.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 45 | 99 | $14,949 | $7,207 | 48.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 19 | 22 | $6,622 | $3,063 | 46.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 20 | 20 | $4,839 | $1,423 | 29.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 16 | 45 | $2,385 | $537.75 | 22.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2021 | 15 | 15 | $795.00 | $265.85 | 33.4% |
About Dr. Gerald Colvin, DO
Dr. Gerald Colvin, DO is a Hematology & Oncology healthcare provider based in Wakefield, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1417954199.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gerald Colvin, DO has received a total of $280,772 in payments from pharmaceutical and medical device companies, with $43,960 received in 2024. These payments were reported across 684 transactions from 65 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($185,082).
As a Medicare-enrolled provider, Colvin has provided services to 1,795 Medicare beneficiaries, totaling 3,841 services with total Medicare billing of $336,839. Data is available for 4 years (2020–2023), covering 32 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Wakefield, RI
- Active Since 07/07/2005
- Last Updated 09/09/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1417954199
Products in Payments
- OPDIVO (Biological) $58,976
- EMPLICITI (Biological) $31,134
- Rezlidhia (Drug) $26,280
- Tavalisse (Drug) $24,722
- Kyprolis (Biological) $24,487
- IMBRUVICA (Drug) $18,360
- Kyprolis (Drug) $15,303
- XGEVA (Biological) $8,614
- LIBTAYO (Biological) $5,291
- Avastin (Biological) $4,265
- XARELTO (Drug) $3,755
- AKYNZEO (Drug) $3,639
- Tecartus (Drug) $3,300
- TECENTRIQ (Biological) $2,712
- ONIVYDE (Drug) $1,400
- Copiktra (Drug) $1,320
- Alecensa (Biological) $1,250
- Stivarga (Drug) $1,238
- Revlimid (Drug) $514.58
- DARZALEX (Biological) $472.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Wakefield
Dr. James Smythe, Md, MD
Hematology & Oncology — Payments: $1,907
Hematology & Oncology $1,907
Sylvia Alarcon Velasco, M.d, M.D
Hematology & Oncology — Payments: $906.29
Hematology & Oncology $906.29
Nancy Morin, Md, MD
Hematology & Oncology — Payments: $551.42
Hematology & Oncology $551.42
Dr. Jean Lee, Md, MD
Hematology & Oncology — Payments: $218.38
Hematology & Oncology $218.38